VDSCX
Price
$21.42
Change
+$0.05 (+0.23%)
Updated
Jun 2 closing price
Net Assets
397.97M
VSTSX
Price
$358.78
Change
+$0.87 (+0.24%)
Updated
Jun 2 closing price
Net Assets
2.2T
Interact to see
Advertisement

VDSCX vs VSTSX

Header iconVDSCX vs VSTSX Comparison
Open Charts VDSCX vs VSTSXBanner chart's image
VDSCX vs VSTSX Comparison Chart in %
View a ticker or compare two or three
VS
VDSCX vs. VSTSX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is VDSCX is a Buy and VSTSX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VSTSX has more cash in the bank: 2.2T vs. VDSCX (398M). VSTSX pays higher dividends than VDSCX: VSTSX (1.03) vs VDSCX (0.04). VDSCX was incepted earlier than VSTSX: VDSCX (24 years) vs VSTSX (10 years). VDSCX (4.93) is less costly to investors than VSTSX (0.01). VDSCX is a more actively managed with annual turnover of: 92.00 vs. VSTSX (3.00). VDSCX has a lower initial minimum investment than VSTSX: VDSCX (2500) vs VSTSX (5000000000). VSTSX annual gain was more profitable for investors over the last year : 28.25 vs. VDSCX (16.00). VSTSX return over 5 years is better than : 72.54 vs. VDSCX (5.78).
VDSCXVSTSXVDSCX / VSTSX
Total Expense Ratio2.020.0120,200%
Annual Report Gross Expense Ratio4.930.0149,300%
Fund Existence24 years10 years-
Gain YTD9.53411.38984%
Front LoadN/AN/A-
Min. Initial Investment250050000000000%
Min. Initial Investment IRAN/AN/A-
Net Assets398M2.2T0%
Annual Yield % from dividends0.041.034%
Returns for 1 year16.0028.2557%
Returns for 3 years28.6376.1138%
Returns for 5 years5.7872.548%
Returns for 10 years23.66249.299%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NVEC112.2511.30
+11.19%
NVE Corp
WSO363.864.39
+1.22%
Watsco
ITP0.19N/A
-0.52%
IT Tech Packaging
PTHS26.00-0.20
-0.76%
Pelthos Therapeutics Inc
GPCR37.19-1.36
-3.53%
Structure Therapeutics